GH Research (NASDAQ:GHRS) Now Covered by Analysts at Guggenheim

Research analysts at Guggenheim started coverage on shares of GH Research (NASDAQ:GHRS) in a research report issued to clients and investors on Thursday, Marketbeat reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 190.91% from the stock’s previous close.

Several other analysts have also commented on the stock. Royal Bank of Canada assumed coverage on shares of GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 price target on the stock. Canaccord Genuity Group lowered their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Cantor Fitzgerald assumed coverage on shares of GH Research in a research report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Finally, Stifel Nicolaus raised their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $30.86.

GH Research Trading Up 1.1 %

Shares of GH Research stock opened at $11.00 on Thursday. The company has a 50-day moving average of $11.13 and a two-hundred day moving average of $9.19. The stock has a market cap of $572.31 million, a PE ratio of -13.92 and a beta of 0.94. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. On average, sell-side analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares during the last quarter. AdvisorShares Investments LLC boosted its holdings in shares of GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of GH Research in the 4th quarter valued at $44,000. Northern Trust Corp boosted its holdings in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of GH Research in the 4th quarter valued at $117,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).